Filing Analysis
Context Therapeutics Inc. has updated its corporate presentation to be used in meetings with investors and analysts. This is a routine regulatory filing intended to provide updated information regarding the company's business activities.
📋 Key Facts
- Filed on August 5, 2026
- Company updated its corporate presentation (Exhibit 99.1)
- The update is for use in meetings with investors, analysts, and other stakeholders
Context Therapeutics Inc. received a notification from Nasdaq stating it is non-compliant with the Minimum Bid Price Rule (Rule 5550(a)(2)) after failing to maintain a $1.00 closing bid price for 30 consecutive business days. The company has an initial 180-day period, expiring January 25, 2027, to regain compliance.
🚩 Red Flags
- Delisting notice (Nasdaq Rule 5550(a)(2))
- Failure to maintain minimum bid price of $1.00
- Risk of delisting if compliance is not met by January 25, 2027
📋 Key Facts
- Received written notice from Nasdaq Listing Qualifications Department on July 29, 2026.
- Non-compliance due to failure to maintain a $1.00 minimum closing bid price for 30 consecutive business days.
- Initial compliance period expires January 25, 2027.
- To regain compliance, the stock must close at $1.00 or more for at least 10 consecutive business days.
- Eligibility for a second 180-day extension is contingent upon meeting market value requirements and intent to cure.
Context Therapeutics held its Annual Meeting of Stockholders on June 24, 2026, where shareholders approved several key items. The most significant outcome was the approval to increase authorized common stock from 200 million to 300 million shares.
🚩 Red Flags
- Increase in authorized share count (from 200M to 300M) can lead to future dilution if used for equity financing.
📋 Key Facts
- Annual Meeting held on June 24, 2026.
- Stockholders approved an amendment to increase authorized common stock from 200,000,000 to 300,000,000 shares.
- Seven directors were elected to the Board of Directors, including Dr. Philip Kantoff and Martin Lehr.
- CohnReznick LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- Quorum was established with approximately 79.27% of shares represented (72,830,990 shares).
Context Therapeutics Inc. issued a current report to disclose the publication of an updated corporate presentation and the announcement of positive interim efficacy and safety results from its Phase 1 clinical trial for CTIM-76.
📋 Key Facts
- The company announced positive interim efficacy and safety results for CTIM-76, a Claudin 6 x CD3 T cell engaging bispecific antibody, on June 15, 2026.
- An updated corporate presentation was posted to the company website on June 15, 2026.
- A conference call was held on June 15, 2026, to discuss the Phase 1 clinical trial data.
Context Therapeutics amended its license agreement with BioAtla to convert its rights to the CT-202 antibody program into an irrevocable, royalty-free, and fully paid-up license. In exchange for a total of $6.5 million in payments, the company eliminated all future milestone and royalty obligations to BioAtla.
🚩 Red Flags
- Significant near-term cash commitment of $6.5 million for a micro-cap company.
📋 Key Facts
- Amendment Date: May 14, 2026.
- The company will pay BioAtla $4.5 million within five business days and an additional $2.0 million by August 1, 2026.
- The license for CT-202 (a Nectin-4 x CD3 T cell engaging bispecific antibody) is now irrevocable, royalty-free, and non-terminable.
- Eliminated all future milestone payments, royalties, and research and development reporting obligations to BioAtla.
- BioAtla no longer has the right to terminate the License Agreement.
Context Therapeutics settled a stockholder class action lawsuit challenging its corporate charter, resulting in the court-ordered invalidation of staggered board terms and 'for-cause' director removal provisions. A third-party service provider paid the $850,000 mootness fee on the company's behalf to resolve the litigation.
🚩 Red Flags
- Court-ordered invalidation of existing corporate governance structures indicates previous non-compliance with Delaware law.
- The identity of the 'third party service provider' paying the $850,000 fee is not disclosed, creating ambiguity regarding the nature of the relationship or potential future obligations.
📋 Key Facts
- The Delaware Court of Chancery ruled Article V, Section 2 and Article VI, Section 1 of the Company's Charter invalid and unenforceable on March 11, 2026.
- The invalidated provisions previously mandated three-year director terms and restricted director removal to 'for cause' only.
- A 'Mootness Fee' of $850,000 was ordered to be paid to the plaintiff's counsel (Vladimir Gusinsky Revocable Trust).
- On April 30, 2026, the Company entered into a Letter Agreement where an unnamed third-party service provider agreed to pay the $850,000 fee.
- The fee was paid in full by the provider on May 1, 2026.
- The legal action will be officially closed following the Company's annual meeting scheduled for June 24, 2026.
Context Therapeutics announced that the FDA has granted Fast Track designation to its investigational bispecific antibody, CTIM-76, for the treatment of platinum-resistant ovarian cancer.
📋 Key Facts
- On April 2, 2026, the FDA granted Fast Track designation to CTIM-76.
- CTIM-76 is a Claudin 6 x CD3 T cell engaging bispecific antibody.
- The designation applies to patients with platinum-resistant ovarian cancer who have failed all standard of care therapies.
- The announcement was made via press release and filed under Items 7.01 and 8.01.
Context Therapeutics Inc. updated its corporate presentation for use in investor and analyst meetings. While most of the presentation was furnished under Item 7.01, the company specifically incorporated slides 15 and 32 into Item 8.01, making that specific content legally 'filed' under the Exchange Act.
📋 Key Facts
- The filing was made on March 23, 2026.
- The corporate presentation is included as Exhibit 99.1.
- Slides 15 and 32 of the presentation are incorporated by reference into Item 8.01, which is a common practice when specific data points are deemed material and need to be 'filed' rather than just 'furnished'.
- The presentation is intended for upcoming meetings with investors and analysts.
Context Therapeutics amended its Charter following a Delaware Court of Chancery judgment that invalidated its staggered board and 'for cause' removal provisions. As a result, all current directors will stand for election at the 2026 Annual Meeting, and stockholders may now remove directors with or without cause.
🚩 Red Flags
- Stockholder class action litigation successfully challenged the company's governance structure.
- Extremely tight deadline for stockholder nominations: the 8-K was filed on March 13, 2026, with a nomination deadline of March 14, 2026.
📋 Key Facts
- The Delaware Court of Chancery approved a Stipulated Judgment on March 11, 2026, in a stockholder class action lawsuit.
- Article V, Section 2 (three-year director terms) and Article VI, Section 1 (removal only for cause) of the Charter were ruled invalid and unenforceable.
- A Certificate of Correction was filed on March 11, 2026, to remove these provisions from the Charter.
- The terms of all current Board members will now expire at the 2026 Annual Meeting scheduled for June 24, 2026.
- The deadline for stockholders to nominate directors or submit proposals for the 2026 Annual Meeting is March 14, 2026.
Context Therapeutics has entered into a stipulated judgment to settle a stockholder class action lawsuit, resulting in the invalidation of key corporate governance provisions in its Charter. The settlement mandates the transition from three-year staggered director terms to one-year terms and removes the restriction that directors can only be removed for cause.
🚩 Red Flags
- The company's existing Charter was found to contain legally unenforceable provisions under Delaware law.
- The governance changes were forced by a stockholder class action lawsuit rather than proactive board action.
📋 Key Facts
- A Stipulated Judgment was filed on February 24, 2026, in the Delaware Court of Chancery to settle a class action filed by the Vladimir Gusinsky Revocable Trust.
- Article V, Section 2 of the Charter (3-year director terms) and Article VI, Section 1 (removal only for cause) were deemed invalid and unenforceable.
- The Company will file a Certificate of Correction with the Delaware Secretary of State to nullify these provisions.
- The 2026 Annual Meeting of Stockholders is scheduled for June 24, 2026, with a record date of April 27, 2026.
- Stockholders wishing to nominate directors or bring proposals must do so by March 14, 2026.
- The Company will propose electing directors to one-year terms at the upcoming Annual Meeting.
Context Therapeutics Inc. has updated its corporate presentation to be used in meetings with investors and analysts as of January 8, 2026.
📋 Key Facts
- The company released an updated corporate presentation (Exhibit 99.1) on January 8, 2026.
- The update is intended for use in investor and analyst meetings.
- Information provided under Item 7.01 is furnished but not considered 'filed' for purposes of Section 18 liability.
Context Therapeutics released its Q3 2025 financial results and provided clinical pipeline updates for its bispecific T cell engager (TCE) programs. The company reported positive safety profiles in ongoing Phase 1 trials for CTIM-76 and CT-95, with no dose-limiting toxicities observed to date.
📋 Key Facts
- Released Q3 2025 operating and financial results via press release (Exhibit 99.2).
- CTIM-76: Enrolled 12 patients; preliminary RECIST responses observed in Cohort 3; no CRS > Grade 1 or DLTs reported.
- CTIM-76: Anticipates providing interim Phase 1a data and dose selection in Q2 2026.
- CT-95: Enrolled 6 patients; no CRS > Grade 2 or DLTs reported; initial Phase 1a data expected mid-2026.
- CT-202: Regulatory filings for first-in-human trials expected in Q2 2026.
Context Therapeutics Inc. has amended its existing At-The-Market (ATM) sales agreement with Leerink Partners LLC to increase the aggregate offering capacity by $75 million. The company is also transitioning from a prior ATM prospectus to a new registration statement for these equity sales.
🚩 Red Flags
- Increased reliance on equity dilution to fund operations (R&D and working capital).
- Termination of a previous ATM prospectus in favor of a new one suggests a shift in financing structure or registration strategy.
📋 Key Facts
- Entered into Amendment No. 1 to Sales Agreement on October 24, 2025.
- Increased aggregate offering amount by $75 million (exclusive of previous sales).
- Prior ATM prospectus had already raised approximately $15 million via the sale of 14,705,882 shares.
- Agent (Leerink Partners LLC) to receive a commission of up to 3.0% on gross proceeds.
- Proceeds are intended for R&D, working capital, general corporate purposes, and potential asset acquisitions.
- The company is suspending/terminating the use of the Prior ATM Sales Prospectus as of October 24, 2025.
Context Therapeutics Inc. has successfully regained compliance with Nasdaq's Minimum Bid Price Rule (Rule 5550(a)(2)). After a period of non-compliance and receiving an extension, the company's stock price met the $1.00 requirement for 10 consecutive business days as of October 17, 2025.
🚩 Red Flags
- History of non-compliance with Nasdaq's Minimum Bid Price Rule (previously faced a deadline of August 26, 2025).
📋 Key Facts
- Company regained compliance with Nasdaq Listing Rule 5550(a)(2) on October 17, 2025.
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days.
- The company had previously received an extension from Nasdaq until February 23, 2026.
- Nasdaq has officially considered the minimum bid price compliance matter closed.
Context Therapeutics Inc. has received a 180-day extension from Nasdaq to regain compliance with the Minimum Bid Price Rule (Rule 5550(a)(2)). The company must maintain a minimum closing bid price of $1.00 per share by February 23, 2026, or face potential delisting.
🚩 Red Flags
- Delisting risk: Failure to meet minimum bid price requirements puts the company at risk of being removed from Nasdaq.
- Potential for reverse stock split: The mention of a reverse split indicates significant downward pressure on the share price and potential dilution/structural changes that often negatively impact micro-cap sentiment.
📋 Key Facts
- Nasdaq granted an extension until February 23, 2026, to regain compliance with the Minimum Bid Price Rule.
- The company failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days as of the previous notice on February 27, 2025.
- Management explicitly mentioned that a reverse stock split is being considered as a potential option to regain compliance.
Context Therapeutics Inc. held its 2025 Annual Meeting of Stockholders where shareholders approved a proposal to implement a reverse stock split with a ratio between 1-for-5 and 1-for-50, as determined by the Board.
🚩 Red Flags
- Approval of a significant reverse stock split (up to 1-for-50) is often used to combat low share prices and maintain Nasdaq listing compliance.
- The wide range of the potential split ratio (1-for-5 to 1-for-50) indicates high volatility or uncertainty regarding the required price correction.
📋 Key Facts
- Annual Meeting held on June 12, 2025.
- Quorum was established with 66,716,026 shares (74.37% of outstanding shares) present or represented by proxy.
- Stockholders ratified the appointment of CohnReznick LLP as independent auditor for FY2025.
- Stockholders approved a reverse stock split ratio ranging from 1-for-5 to 1-for-50.
Context Therapeutics Inc. has updated its corporate presentation to be used in meetings with investors and analysts. The update is filed under Item 7.01 (Regulation FD Disclosure) and incorporates specific information from the presentation into Item 8.01.
📋 Key Facts
- The company updated its corporate presentation on June 2, 2025.
- The presentation is intended for use in meetings with investors, analysts, and other stakeholders.
- Exhibit 99.1 contains the full updated presentation.
- Specific information from Slide 17 of Exhibit 99.1 is incorporated by reference into Item 8.01 (Other Events).
Context Therapeutics announced the commencement of its Phase 1 clinical trial for CT-95, with the first patient having been dosed on April 9, 2025. The company expects to release initial data from this trial in mid-2026.
📋 Key Facts
- First patient has been dosed in the Phase 1 clinical trial evaluating CT-95.
- Initial data for the CT-95 Phase 1 trial is anticipated in mid-2026.
- The announcement was made via a press release on April 9, 2025.
Context Therapeutics Inc. received a notice from Nasdaq stating it is non-compliant with the Minimum Bid Price Rule after failing to maintain a $1.00 closing bid price for 30 consecutive business days.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price of $1.00 for 30 consecutive business days
- Risk of potential delisting if compliance is not achieved by August 26, 2025
📋 Key Facts
- Received written notification from Nasdaq on February 27, 2025.
- Non-compliance is due to violation of Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Rule).
- The company has an initial 180-day period to regain compliance, ending August 26, 2025.
- Compliance can be achieved if the stock closes at $1.00 or more for 10 consecutive business days.
- A second 180-day grace period may be available if the initial period is not met.
Context Therapeutics announced a clinical milestone regarding its CTIM-76 program. The company has successfully dosed the first patient in its Phase 1 clinical trial.
📋 Key Facts
- First patient has been dosed in the Phase 1 clinical trial evaluating CTIM-76.
- Initial data from the CTIM-76 Phase 1 trial is anticipated to be shared in the first half of 2026.
- The announcement was made via press release on January 14, 2025.
Context Therapeutics announced the resignation of Board member Richard Berman and the simultaneous appointment of Andy Pasternak as Chairperson of the Board. The transition is described as non-dispute related, with Mr. Pasternak bringing significant biotechnology leadership experience.
🚩 Red Flags
- None identified; resignation was explicitly stated as not being due to disagreements.
📋 Key Facts
- Richard Berman resigned from the Board effective January 12, 2025; resignation was not due to any disagreement with the Company.
- Andy Pasternak appointed as Chairperson of the Board, effective January 13, 2025.
- Mr. Pasternak also appointed to the Audit and Compensation Committees; Dr. Karen L. Smith named Chairperson of the Compensation Committee.
- Mr. Pasternak was granted 20,685 stock options vesting in June 2025 or at the 2025 annual meeting.
- Mr. Pasternak's background includes leadership roles at Bain & Company and Horizon Therapeutics plc.
Context Therapeutics Inc. completed the sale of 14,705,882 shares of common stock on December 23, 2024. The transaction generated approximately $15 million in gross proceeds and was executed via a sales agreement with Leerink Partners LLC.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 14.7 million new shares.
📋 Key Facts
- Sold 14,705,882 shares of common stock.
- Aggregate gross proceeds: approximately $15 million.
- Transaction date: December 23, 2024.
- Agent: Leerink Partners LLC.
- Purchaser identified as MPM BioImpact LLC.
Context Therapeutics Inc. entered into an at-the-market (ATM) sales agreement with Leerink Partners LLC to offer up to $75 million in common stock. The proceeds are intended for R&D, working capital, and potential asset acquisitions.
🚩 Red Flags
- Potential dilution of existing shareholders through the issuance of new common stock.
- The use of an ATM offering often indicates a need for immediate liquidity to fund ongoing operations (burn rate management).
📋 Key Facts
- Entered into a Sales Agreement with Leerink Partners LLC on December 2, 2024.
- Aggregate offering amount of up to $75.0 million in common stock.
- Agent (Leerink Partners) will receive a 3.0% commission on gross proceeds.
- The offering is an 'at-the-market' (ATM) type under Rule 415.
- Proceeds are earmarked for R&D, working capital, and general corporate purposes including asset acquisitions.
Context Therapeutics entered into an exclusive, worldwide license agreement with BioAtla, Inc. to develop and commercialize two antibodies, including a Nectin-4 x CD3 T cell engaging bispecific antibody (CT-202). The deal includes an upfront payment of $11.0 million and significant milestone potential totaling up to $122.5 million plus royalties.
🚩 Red Flags
- Cash runway guidance: Company expects current cash to fund operations into 2027, but notes that estimates are based on imprecise assumptions and capital could be utilized sooner.
- BioAtla has the right to terminate if the Company fails to conduct R&D activities for eight consecutive quarters prior to regulatory approval.
📋 Key Facts
- Entered into exclusive license agreement with BioAtla, Inc. on September 23, 2024.
- Acquired rights to two assets, including BA3362 (renamed CT-202), a Nectin-4 x CD3 T cell engaging bispecific antibody.
- Upfront payment of $11.0 million due to BioAtla.
- BioAtla is eligible for up to $4.0 million in near-term milestones and $118.5 million in additional development/commercial milestones.
- Agreement includes tiered royalties on future net sales of products containing the Assets.
- Company anticipates filing an IND application for CT-202 in mid-2026.
- CTIM-76 Phase 1 trial is currently screening; first patient dosing expected Oct/Nov 2024.
Context Therapeutics Inc. held a Special Meeting of Stockholders on September 17, 2024, where shareholders approved an amendment to increase the authorized number of common shares from 100 million to 200 million.
🚩 Red Flags
- Significant increase in authorized share count (doubling) often precedes dilutive equity offerings to raise capital.
📋 Key Facts
- Stockholders approved increasing authorized common stock from 100,000,000 to 200,000,000 shares.
- The Special Meeting was held on September 17, 2024.
- Quorum consisted of 43,251,969 shares (57.67% of outstanding shares).
- Proposal 1 received 42,389,461 votes 'For' and 790,853 votes 'Against'.
- The company is an emerging growth company.
Context Therapeutics Inc. expanded its Board of Directors from five to seven members by appointing Dr. Karen L. Smith and Dr. Luke Walker. Both appointees bring extensive biopharmaceutical leadership experience, having previously held roles at companies such as Harpoon Therapeutics and Jazz Pharmaceuticals.
📋 Key Facts
- Board size increased from 5 to 7 members.
- Dr. Karen L. Smith appointed to the Board and Compensation Committee; term expires at 2027 annual meeting.
- Dr. Luke Walker appointed to the Board and Nominating Committee; term expires at 2027 annual meeting.
- Both directors granted options to purchase 19,315 shares of common stock, vesting June 13, 2025, or at the 2025 annual meeting.
- Annual cash retainer for non-employee directors is $40,000.
Context Therapeutics Inc. has acquired CT-95, a mesothelin x CD3 T cell engaging bispecific antibody, from Link (assignment for the benefit of creditors), LLC for a one-time payment of $3.75 million. The company plans to initiate Phase 1 clinical trials for this asset in Q1 2025.
🚩 Red Flags
- Seller was an entity in 'assignment for the benefit of creditors' (liquidation process), which can sometimes indicate distressed asset quality or complex title issues, though common in biotech.
- The company is relying on 'existing cash' to fund upcoming clinical trials, which may imply a limited runway if trial costs exceed projections.
📋 Key Facts
- Acquired CT-95 (formerly LNK-101) from Link (assignment for the benefit of creditors), LLC.
- Transaction closed on July 9, 2024.
- Purchase price was a one-time payment of $3.75 million.
- Assets acquired include patent rights, know-how, regulatory filings, and drug substance/product inventory.
- Company expects to initiate Phase 1 clinical trials in Q1 2025.
- The company intends to fund the dose escalation portion of the trial using existing cash.
Context Therapeutics Inc. held its Annual Meeting of Stockholders on June 13, 2024. The meeting resulted in the ratification of CohnReznick LLP as the independent auditor and the election of five directors to the Board.
📋 Key Facts
- Annual Meeting held on June 13, 2024.
- Quorum was established with 8,486,458 shares (53.15% of outstanding shares) present or represented by proxy.
- CohnReznick LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Five directors were elected: Richard Berman, Dr. Philip Kantoff, Martin Lehr, Jennifer Evans Stacey, and Linda West.
Context Therapeutics Inc. entered into a $100 million private placement of common stock and pre-funded warrants to fund the clinical development of its CTIM-76 program. The financing includes significant dilution via pre-funded warrants and carries restrictive covenants for both the company and insiders.
🚩 Red Flags
- Significant dilution: The issuance of over 59 million shares and ~5.5 million warrants represents a massive increase in share count.
- Restrictive Covenants: A 90-day standstill prevents the company from issuing other securities or filing other registration statements; 60-day lock-up for officers/directors.
- Pre-funded Warrants: These are often used to circumvent certain regulatory hurdles but result in immediate dilution upon exercise (which is nearly instantaneous at $0.001).
📋 Key Facts
- Private placement of 59,032,259 shares at $1.55 per share.
- Issuance of 5,482,741 pre-funded warrants at $1.549 per warrant (exercise price of $0.001).
- Expected gross proceeds: approximately $100 million.
- Use of proceeds: R&D for CTIM-76, working capital, and general corporate purposes.
- The company expects the financing to extend cash runway into 2028.
- FDA cleared IND application for CTIM-76 (Claudin 6 x CD3 bispecific antibody).
- First patient enrollment for Phase 1 trial expected in mid-2024.
Context Therapeutics Inc. announced the submission of an Investigational New Drug (IND) application to the FDA on March 28, 2024. The application is for a Phase 1 clinical trial of CTIM-76, a bispecific antibody targeting CLDN6-positive tumors.
📋 Key Facts
- Submitted IND application to the FDA on March 28, 2024.
- The application supports a Phase 1 clinical trial for CTIM-76.
- CTIM-76 is a Claudin 6 (CLDN6) x CD3 bispecific antibody.
- Target indication: CLDN6-positive tumors.
Context Therapeutics Inc. has amended and restated its Bylaws, effective March 19, 2024. The changes primarily focus on streamlining stockholder meeting procedures and implementing mechanisms related to Rule 14a-19 proxy solicitations.
🚩 Red Flags
- Reduction of quorum requirements can sometimes be used to make it easier for a controlling group or management to pass measures, though common in micro-caps.
📋 Key Facts
- Board of Directors approved the amendment and restatement of the Company's Bylaws on March 19, 2024.
- Quorum requirement for stockholder meetings reduced to one-third of issued and outstanding capital stock.
- Eliminated the requirement to produce/keep a stockholder list for examination at each meeting.
- Implemented new procedural mechanisms regarding Rule 14a-19 (proxy solicitations) for director nominations.
- Requirement for stockholders soliciting non-company proxies to certify compliance with Rule 14a-19 and provide evidence upon request.
Context Therapeutics amended its licensing agreement with Integral Molecular due to the discovery of potential third-party intellectual property infringement regarding its CTIM-76 asset. The amendment significantly reduces milestone payments and royalty rates owed to Integral.
🚩 Red Flags
- Significant reduction in potential future cash inflows (milestones) from a key partner.
- Intellectual property risk: Potential infringement of third-party patents covering the lead asset (CTIM-76).
- Uncertainty regarding the ability to defend against or license necessary IP on commercially reasonable terms.
📋 Key Facts
- The Second Amendment was executed on February 29, 2024.
- Development/regulatory milestones reduced from $55 million to $15 million.
- Sales milestones reduced from $130 million to $12.5 million.
- Royalty rate changed from a tiered 8-12% to a flat 6% (effective no sooner than Feb 1, 2034).
- The license grant is now narrowed exclusively to the CTIM-76 asset.
- Company identified issued patents in the US and foreign jurisdictions expiring Jan 2034 that may cover CTIM-76.